Citi lowered the firm’s price target on Baxter to $45 from $47 and keeps a Neutral rating on the shares. The analyst adjusted price targets in the medical technology space post the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BAX: